QuiaPEG

Newsroom

Se nyheter från:
Page:
123456
Oct 10, 2018

QuiaPEG Pharmaceuticals Holding AB (publ) receives so-called "Notice of Allowance" for granting of a patent in the United States.

Sept 27, 2018

QuiaPEG continues the commercialization of avUni-Qleaver® together with Sinopeg by exhibiting in Sinopeg's booth at the major trade fair CPHI in madrid, 9-11 october.

Sept 13, 2018

QuiaPEG Pharmaceuticals Holding AB (publ) today announced that a patent application has been filed with the U.S. Patent Office. If the application is subsequently granted, QuiaPEG will obtain a patent protection to at least the end of 2038.

Sept 03, 2018

QuiaPEG Pharmaceuticals Holding AB (publ), which develops improved and patentable versions of clinically validated or approved drugs using the company's unique technology platform, announces that the company's CEO, Marcus Bosson, has on 31/8 and 3/9 in total acquired 100,000 shares at an average price of SEK 2.02 and that on 3 September, Board member Anders Vedin has acquired 99,806 shares at an average price of SEK 2.14.

Page:
123456
Contact
QuiaPEG Pharmaceuticals Holding AB

Virdings Allé 32 B
754 54 Uppsala
Sweden
+46 (0) 70 693 12 53
info@quiapeg.com

User terms & privacy policy
Send a message